These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Jung C; Engelmann E; Borner K; Offermann G Transplant Proc; 2001; 33(7-8):3621-3. PubMed ID: 11750538 [No Abstract] [Full Text] [Related]
3. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888 [TBL] [Abstract][Full Text] [Related]
4. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Singh N Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841 [TBL] [Abstract][Full Text] [Related]
5. Preemptive ganciclovir therapy in renal transplantation. Tamm M; Cathomas G; Thiel G Ann Intern Med; 1996 Apr; 124(7):693-4. PubMed ID: 8607603 [No Abstract] [Full Text] [Related]
6. Prevention of cytomegalovirus disease after heart transplantation: preemptive therapy with 7 days' intravenous ganciclovir. Paniagua MJ; Crespo-Leiro MG; De la Fuente L; Tabuyo T; Mosquera I; Cañizares A; Naya C; Fariña P; Juffé A; Castro-Beiras A Transplant Proc; 2002 Feb; 34(1):69-70. PubMed ID: 11959189 [No Abstract] [Full Text] [Related]
8. Effective strategies to prevent cytomegalovirus disease after renal transplantation. Chapman JR Transplant Proc; 2000 Nov; 32(7):1508-9. PubMed ID: 11119809 [No Abstract] [Full Text] [Related]
9. Prophylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem. Kuypers DR; Vanrenterghem YF Nephrol Dial Transplant; 1999 Oct; 14(10):2304-8. PubMed ID: 10528649 [No Abstract] [Full Text] [Related]
11. Preemptive treatment with oral ganciclovir for pediatric renal transplantation. Melgosa Hijosa M; García Meseguer C; Peña Garcia P; Alonso Melgar A; Espinosa Román L; Peña Carrión A; Navarro Torres M Clin Nephrol; 2004 Apr; 61(4):246-52. PubMed ID: 15125030 [TBL] [Abstract][Full Text] [Related]
12. Prophylaxis of cytomegalovirus disease with intravenous ganciclovir in renal transplantation. Sancho A; Górriz JL; Crespo JF; Avila A; Alcaraz MJ; García Ramos JL; Pallardó LM Transplant Proc; 1999 Sep; 31(6):2337-8. PubMed ID: 10500606 [No Abstract] [Full Text] [Related]
13. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial. Pouteil-Noble C; Megas F; Chapuis F; Bosshard S; Colin C; Hadj-Aissa A; Pozet N; Martin X; Lefrançois N; Garnier JL; Aymard M; Touraine JL Transplant Proc; 1996 Oct; 28(5):2811. PubMed ID: 8908072 [No Abstract] [Full Text] [Related]
14. Pharmacoeconomic analysis of preemptive gancyclovir therapy in the prevention of cytomegalovirus infections in high-risk renal graft recipients. Chak WL; Choi KS; Wong KM; Chan YH; Chau KF; Li CS Transplant Proc; 2003 Feb; 35(1):280-1. PubMed ID: 12591399 [No Abstract] [Full Text] [Related]
15. Preemptive therapy for the prevention of cytomegalovirus disease following heart transplantation directed by PP65 antigenemia. Villa M; Lage E; Ballesteros S; Cañas E; Sánchez M; Ordóñez A; Borrego JM; Hinojosa R; Cisneros JM Transplant Proc; 2003 Mar; 35(2):732-4. PubMed ID: 12644115 [No Abstract] [Full Text] [Related]
16. Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients. Brennan DC; Garlock KA; Lippmann BJ; Buller RS; Gaudreault-Keener M; Lowell JA; Miller SB; Shenoy S; Howard TK; Storch GA Transplant Proc; 1997; 29(1-2):809-11. PubMed ID: 9123536 [No Abstract] [Full Text] [Related]
17. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523 [TBL] [Abstract][Full Text] [Related]
18. Preemptive therapy for cytomegalovirus with oral ganciclovir after liver transplantation. Singh N Transplantation; 2002 Jun; 73(12):1977; author reply 1977-8. PubMed ID: 12131704 [No Abstract] [Full Text] [Related]
19. Cytomegalovirus infection in kidney transplantation: prophylaxis and management. Bulinski P; Toledo-Pereyra LH; Dalal S; Hernandez G Transplant Proc; 1996 Dec; 28(6):3310-1. PubMed ID: 8962286 [No Abstract] [Full Text] [Related]
20. Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients. Díaz-Pedroche C; Lumbreras C; Del Valle P; San Juan R; Hernando S; Folgueira D; Andrés A; Delgado J; Meneu JC; Morales JM; Moreno E; Aguado JM Transplant Proc; 2005 Nov; 37(9):3766-7. PubMed ID: 16386532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]